TY - JOUR
T1 - Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan
T2 - a nationwide survey analysis
AU - Ito, Tetsuhide
AU - Igarashi, Hisato
AU - Nakamura, Kazuhiko
AU - Sasano, Hironobu
AU - Okusaka, Takuji
AU - Takano, Koji
AU - Komoto, Izumi
AU - Tanaka, Masao
AU - Imamura, Masayuki
AU - Jensen, Robert T.
AU - Takayanagi, Ryoichi
AU - Shimatsu, Akira
N1 - Funding Information:
This study was supported in part by Grants-in-Aid from the National Cancer Center Research and Development Fund (Grant Number: 21-8-6). The authors are very grateful to the doctors who responded to the questionnaires.
Publisher Copyright:
© 2014, Springer Japan.
PY - 2014/1
Y1 - 2014/1
N2 - Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.
AB - Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.
KW - Epidemiology
KW - Gastrointestinal neuroendocrine tumor
KW - Nation-wide survey
KW - Neuroendocrine tumor
KW - Pancreatic neuroendocrine tumor
UR - http://www.scopus.com/inward/record.url?scp=84893194219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893194219&partnerID=8YFLogxK
U2 - 10.1007/s00535-014-0934-2
DO - 10.1007/s00535-014-0934-2
M3 - Article
C2 - 24499825
AN - SCOPUS:84893194219
SN - 0944-1174
VL - 50
SP - 58
EP - 64
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 1
ER -